Annual CFO
-$31.41 M
-$7.60 M-31.92%
December 31, 2023
Summary
- As of February 8, 2025, SLS annual cash flow from operations is -$31.41 million, with the most recent change of -$7.60 million (-31.92%) on December 31, 2023.
- During the last 3 years, SLS annual CFO has fallen by -$20.99 million (-201.53%).
- SLS annual CFO is now -1387.22% below its all-time high of -$2.11 million, reached on December 31, 2006.
Performance
SLS Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$7.81 M
+$1.88 M+19.38%
September 30, 2024
Summary
- As of February 8, 2025, SLS quarterly cash flow from operations is -$7.81 million, with the most recent change of +$1.88 million (+19.38%) on September 30, 2024.
- Over the past year, SLS quarterly CFO has dropped by -$2.98 million (-61.78%).
- SLS quarterly CFO is now -131.14% below its all-time high of $25.07 million, reached on December 31, 2016.
Performance
SLS Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$33.07 M
-$914.00 K-2.84%
September 30, 2024
Summary
- As of February 8, 2025, SLS TTM cash flow from operations is -$33.07 million, with the most recent change of -$914.00 thousand (-2.84%) on September 30, 2024.
- Over the past year, SLS TTM CFO has dropped by -$1.66 million (-5.30%).
- SLS TTM CFO is now -650.77% below its all-time high of $6.00 million, reached on June 30, 2017.
Performance
SLS TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
SLS Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -31.9% | -61.8% | -5.3% |
| 3 y3 years | -201.5% | -3.2% | -8.1% |
| 5 y5 years | -3.3% | -3.2% | -8.1% |
SLS Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -31.9% | at low | -61.8% | +35.6% | -44.4% | at low |
| 5 y | 5-year | -201.5% | at low | -328.0% | +35.6% | -217.5% | at low |
| alltime | all time | -1387.2% | +34.8% | -131.1% | +59.7% | -650.8% | +36.6% |
SELLAS Life Sciences Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$7.81 M(-19.4%) | -$33.07 M(+2.8%) |
| Jun 2024 | - | -$9.68 M(-10.0%) | -$32.16 M(+7.0%) |
| Mar 2024 | - | -$10.76 M(+123.0%) | -$30.04 M(-4.3%) |
| Dec 2023 | -$31.41 M(+31.9%) | -$4.83 M(-30.0%) | -$31.41 M(-1.0%) |
| Sep 2023 | - | -$6.89 M(-8.9%) | -$31.74 M(+3.7%) |
| Jun 2023 | - | -$7.57 M(-37.6%) | -$30.59 M(+6.3%) |
| Mar 2023 | - | -$12.13 M(+135.4%) | -$28.79 M(+20.9%) |
| Dec 2022 | -$23.81 M(-8.5%) | -$5.15 M(-10.3%) | -$23.81 M(+0.7%) |
| Sep 2022 | - | -$5.75 M(-0.3%) | -$23.63 M(-0.6%) |
| Jun 2022 | - | -$5.76 M(-19.4%) | -$23.77 M(+3.8%) |
| Mar 2022 | - | -$7.15 M(+43.7%) | -$22.90 M(-12.0%) |
| Dec 2021 | -$26.02 M(+149.8%) | -$4.98 M(-15.3%) | -$26.02 M(+47.7%) |
| Sep 2021 | - | -$5.88 M(+20.0%) | -$17.62 M(+14.6%) |
| Jun 2021 | - | -$4.90 M(-52.3%) | -$15.37 M(+10.9%) |
| Mar 2021 | - | -$10.27 M(-399.9%) | -$13.86 M(+33.0%) |
| Dec 2020 | -$10.42 M(-41.0%) | $3.42 M(-194.4%) | -$10.42 M(-42.2%) |
| Sep 2020 | - | -$3.63 M(+7.3%) | -$18.02 M(-1.0%) |
| Jun 2020 | - | -$3.38 M(-50.5%) | -$18.21 M(-6.5%) |
| Mar 2020 | - | -$6.83 M(+63.6%) | -$19.48 M(+10.4%) |
| Dec 2019 | -$17.64 M(-42.0%) | -$4.18 M(+9.3%) | -$17.64 M(-2.1%) |
| Sep 2019 | - | -$3.82 M(-18.0%) | -$18.02 M(-36.5%) |
| Jun 2019 | - | -$4.66 M(-6.7%) | -$28.37 M(-5.5%) |
| Mar 2019 | - | -$4.99 M(+9.6%) | -$30.01 M(-1.4%) |
| Dec 2018 | -$30.42 M(+176.8%) | -$4.55 M(-67.8%) | -$30.42 M(+186.5%) |
| Sep 2018 | - | -$14.16 M(+124.9%) | -$10.62 M(-33.0%) |
| Jun 2018 | - | -$6.30 M(+16.6%) | -$15.84 M(+25.8%) |
| Mar 2018 | - | -$5.40 M(-135.4%) | -$12.59 M(+14.6%) |
| Dec 2017 | -$10.99 M(-7.3%) | $15.25 M(-178.7%) | -$10.99 M(+836.8%) |
| Sep 2017 | - | -$19.39 M(+535.8%) | -$1.17 M(-119.5%) |
| Jun 2017 | - | -$3.05 M(-19.8%) | $6.00 M(-346.4%) |
| Mar 2017 | - | -$3.80 M(-115.2%) | -$2.44 M(-79.4%) |
| Dec 2016 | -$11.85 M(-75.4%) | $25.07 M(-305.3%) | -$11.85 M(-77.3%) |
| Sep 2016 | - | -$12.21 M(+6.2%) | -$52.20 M(+5.6%) |
| Jun 2016 | - | -$11.49 M(-13.1%) | -$49.45 M(-0.7%) |
| Mar 2016 | - | -$13.22 M(-13.5%) | -$49.82 M(+3.4%) |
| Dec 2015 | -$48.16 M | -$15.28 M(+61.6%) | -$48.16 M(+10.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2015 | - | -$9.46 M(-20.2%) | -$43.61 M(-3.7%) |
| Jun 2015 | - | -$11.86 M(+2.6%) | -$45.27 M(-2.4%) |
| Mar 2015 | - | -$11.56 M(+7.7%) | -$46.38 M(+8.2%) |
| Dec 2014 | -$42.87 M(+48.2%) | -$10.73 M(-3.4%) | -$42.87 M(+5.5%) |
| Sep 2014 | - | -$11.12 M(-14.3%) | -$40.63 M(+8.4%) |
| Jun 2014 | - | -$12.97 M(+61.2%) | -$37.49 M(+18.5%) |
| Mar 2014 | - | -$8.05 M(-5.2%) | -$31.65 M(+9.4%) |
| Dec 2013 | -$28.93 M(+37.9%) | -$8.49 M(+6.4%) | -$28.93 M(+12.9%) |
| Sep 2013 | - | -$7.98 M(+12.1%) | -$25.61 M(+17.5%) |
| Jun 2013 | - | -$7.12 M(+33.6%) | -$21.80 M(+1.8%) |
| Mar 2013 | - | -$5.33 M(+3.0%) | -$21.42 M(+2.1%) |
| Dec 2012 | -$20.97 M(+43.0%) | -$5.18 M(+24.3%) | -$20.97 M(+5.1%) |
| Sep 2012 | - | -$4.17 M(-38.3%) | -$19.96 M(+3.9%) |
| Jun 2012 | - | -$6.75 M(+38.1%) | -$19.21 M(+16.3%) |
| Mar 2012 | - | -$4.88 M(+17.2%) | -$16.53 M(+12.7%) |
| Dec 2011 | -$14.67 M(+43.0%) | -$4.17 M(+22.2%) | -$14.67 M(+18.6%) |
| Sep 2011 | - | -$3.41 M(-15.9%) | -$12.37 M(+10.5%) |
| Jun 2011 | - | -$4.06 M(+34.1%) | -$11.19 M(+3.2%) |
| Mar 2011 | - | -$3.03 M(+62.0%) | -$10.84 M(+5.7%) |
| Dec 2010 | -$10.26 M(-12.8%) | -$1.87 M(-16.5%) | -$10.26 M(-12.2%) |
| Sep 2010 | - | -$2.24 M(-39.7%) | -$11.68 M(-6.5%) |
| Jun 2010 | - | -$3.71 M(+51.7%) | -$12.48 M(+8.2%) |
| Mar 2010 | - | -$2.44 M(-25.7%) | -$11.54 M(-1.9%) |
| Dec 2009 | -$11.77 M(+24.8%) | -$3.29 M(+8.0%) | -$11.77 M(+4.9%) |
| Sep 2009 | - | -$3.04 M(+10.1%) | -$11.22 M(+6.5%) |
| Jun 2009 | - | -$2.77 M(+3.5%) | -$10.53 M(+0.9%) |
| Mar 2009 | - | -$2.67 M(-2.3%) | -$10.43 M(+10.6%) |
| Dec 2008 | -$9.43 M(+55.9%) | -$2.73 M(+15.9%) | -$9.43 M(+6.1%) |
| Sep 2008 | - | -$2.36 M(-11.5%) | -$8.89 M(+2.5%) |
| Jun 2008 | - | -$2.67 M(+59.9%) | -$8.67 M(+30.3%) |
| Mar 2008 | - | -$1.67 M(-23.9%) | -$6.65 M(+10.0%) |
| Dec 2007 | -$6.05 M(+186.3%) | -$2.19 M(+2.3%) | -$6.05 M(+56.9%) |
| Sep 2007 | - | -$2.14 M(+230.0%) | -$3.85 M(+125.0%) |
| Jun 2007 | - | -$649.00 K(-39.0%) | -$1.71 M(+61.0%) |
| Mar 2007 | - | -$1.06 M | -$1.06 M |
| Dec 2006 | -$2.11 M | - | - |
FAQ
- What is SELLAS Life Sciences annual cash flow from operations?
- What is the all time high annual CFO for SELLAS Life Sciences?
- What is SELLAS Life Sciences annual CFO year-on-year change?
- What is SELLAS Life Sciences quarterly cash flow from operations?
- What is the all time high quarterly CFO for SELLAS Life Sciences?
- What is SELLAS Life Sciences quarterly CFO year-on-year change?
- What is SELLAS Life Sciences TTM cash flow from operations?
- What is the all time high TTM CFO for SELLAS Life Sciences?
- What is SELLAS Life Sciences TTM CFO year-on-year change?
What is SELLAS Life Sciences annual cash flow from operations?
The current annual CFO of SLS is -$31.41 M
What is the all time high annual CFO for SELLAS Life Sciences?
SELLAS Life Sciences all-time high annual cash flow from operations is -$2.11 M
What is SELLAS Life Sciences annual CFO year-on-year change?
Over the past year, SLS annual cash flow from operations has changed by -$7.60 M (-31.92%)
What is SELLAS Life Sciences quarterly cash flow from operations?
The current quarterly CFO of SLS is -$7.81 M
What is the all time high quarterly CFO for SELLAS Life Sciences?
SELLAS Life Sciences all-time high quarterly cash flow from operations is $25.07 M
What is SELLAS Life Sciences quarterly CFO year-on-year change?
Over the past year, SLS quarterly cash flow from operations has changed by -$2.98 M (-61.78%)
What is SELLAS Life Sciences TTM cash flow from operations?
The current TTM CFO of SLS is -$33.07 M
What is the all time high TTM CFO for SELLAS Life Sciences?
SELLAS Life Sciences all-time high TTM cash flow from operations is $6.00 M
What is SELLAS Life Sciences TTM CFO year-on-year change?
Over the past year, SLS TTM cash flow from operations has changed by -$1.66 M (-5.30%)